Phase 3 Lung Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are willing to take part and sign a consent form agreeing to participate.
• People aged 18 or older, of any gender.
• People who have been diagnosed with a specific type of lung cancer (non-small cell lung cancer, or NSCLC) at stage IIIA or IIIB (with spread to nearby lymph nodes, known as N2), confirmed by laboratory tissue or cell testing, and where surgery to remove the tumour is considered possible.
• People whose cancer has at least one area that can be measured on scans using a standard set of medical guidelines (RECIST 1.1).
• People who are generally well enough to carry out light activity and care for themselves, as rated on a standard health scale (ECOG score of 0 or 1).
• People who are able to provide a tumour tissue sample so that a specific protein (PD-L1) can be tested.
• People whose liver, kidneys, bone marrow, and other organs are functioning well enough to meet the trial's requirements.
• People who are expected to live for at least 6 months.
• People whose overall lung function has been assessed by a surgeon as strong enough to safely undergo the planned lung surgery.

Who may not be able to join:

• People whose cancer has been confirmed to include certain specific types of tumour cells, such as neuroendocrine, sarcomatous/sarcomatoid, adenosquamous, or other special tissue types.
• People who have previously been treated with a drug that targets certain parts of the immune system known as T cell receptors (for example, drugs targeting CTLA-4 or OX-40).
• People who are known to have specific gene changes (EGFR mutation or ALK translocation) in their cancer; and people with non-squamous cell lung cancer whose EGFR and ALK status has not yet been tested.
• People whose tumour is located at the top of the lung (upper lung sulcus tumour), or whose cancer cannot be surgically removed, or has spread to other parts of the body.
• People who have already received any previous treatment aimed at this cancer.
• People with known or suspected lung inflammation (interstitial pneumonia), radiation-related lung damage, or other moderate to severe lung conditions that could interfere with detecting or managing drug-related lung side effects or seriously affect breathing.
• People who have a serious active infection at the time of joining.
• People with heart or brain blood vessel disease that is not well controlled or is considered significant.
• People with an active autoimmune disease (where the immune system attacks the body) that currently requires ongoing medical treatment.
• People who have taken immune-suppressing medications or steroid medications at a dose above a certain level (more than 10 mg per day of prednisone or equivalent) within the 14 days before being assigned to a treatment group.

Important: Always verify eligibility with the trial site directly before applying.